Freedland, S. J., De Giorgi, U., Tutrone, R. F., Karsh, L. I., Ramirez-Backhaus, M., Uchio, E. M., . . . Shore, N. D. (2/20/2025 Supplement 5). Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post hoc analysis. Journal of Clinical Oncology, 43, 179-467.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Freedland, Stephen J., et al. "Secondary Outcomes by Prior Definitive Treatment (tx) in Patients (pts) with High-risk Biochemically Recurrent Prostate Cancer (hrBCR) Treated with Enzalutamide (enza) Monotherapy (mono): EMBARK Post Hoc Analysis."
Journal of Clinical Oncology 43 (2/20/2025 Supplement 5): 179-467.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Freedland, Stephen J., et al. "Secondary Outcomes by Prior Definitive Treatment (tx) in Patients (pts) with High-risk Biochemically Recurrent Prostate Cancer (hrBCR) Treated with Enzalutamide (enza) Monotherapy (mono): EMBARK Post Hoc Analysis."
Journal of Clinical Oncology, vol. 43, 2/20/2025 Supplement 5, pp. 179-467.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.